

File No. DCGI/Misc/2020(96)  
Government of India  
Directorate General of Health Services  
Central Drugs Standard Control Organization  
(DCGI Secretariat)

FDA Bhawan, Kotla Road  
New Delhi-110002  
Dated: 07.04.2020

To,  
All State/UT Drugs Controllers

Subject: Granting permission to manufacturers of industrial oxygen to manufacture oxygen for medical use in the light of Covid-19- Reg.

Sir/ Madam,


As you may be aware, supplemental oxygen therapy is part of clinical management of Covid-19 patient. Therefore, it is imperative to ensure the availability and supply of oxygen for medical use across the country.

In this regard, All India Industrial Gases Manufacturer's Association (AIIGMA) has proposed for allowing manufactures of industrial oxygen to manufacture oxygen for medical use.

In view of above, to ensure the availability and supply of oxygen for medical use, it has been decided in public interest that the premises which are having facility to manufacture industrial oxygen should be granted manufacturing license to manufacture oxygen for medical use within 24 hours of receiving the application, fees, etc. as per the Drugs & Cosmetics Act, 1940 & Rules there under and undertaking in writing to manufacture the medical oxygen in compliance with the standards prescribed in Indian Pharmacopeia and labelling requirement as per the said Act & Rules.

You are requested to take action as above in public interest for granting license to manufacturers of industrial oxygen to manufacture oxygen for medical use in the light of Covid-19.

Yours faithfully,

  
(Dr. V.G. Somani)  
Drugs Controller General (India)

Copy to:  
All stakeholders through CDSCO website

Copy for Information to:

1. PPS to DGHS, Ministry of Health & Family Welfare, Nirman Bhavan, New Delhi.
2. PS to JS (R), Ministry of Health & Family Welfare, Nirman Bhavan, New Delhi.